Monte Rosa Therapeutics, Inc. (GLUE) vs Rigel Pharmaceuticals, Inc. (RIGL)
- Monte Rosa Therapeutics, Inc. GLUE 9.74 −3.75%
- Rigel Pharmaceuticals, Inc. RIGL 45.97 −2.71%
Monte Rosa Therapeutics, Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Monte Rosa Therapeutics, Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($882.6M and $863.4M). Monte Rosa Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.6×. Rigel Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 3.31% against −83.9%. Rigel Pharmaceuticals, Inc. has the higher net margin (116.3% vs −560.9%) and the higher return on invested capital (16.5% vs 0.00%). Across the 16 metrics below, Rigel Pharmaceuticals, Inc. leads on 14 and Monte Rosa Therapeutics, Inc. on 2.
Valuation
Profitability
| Metric | GLUE | RIGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 91.39% | 65.16% |
| Operating margin | (633.04%) | 31.45% | 0.00% |
| Net margin | (560.85%) | 116.30% | 0.00% |
| Free cash flow margin | (111.66%) | 3.19% | 0.00% |
| Return on equity | (42.66%) | 126.90% | (56.36%) |
| Return on assets | (30.67%) | 88.46% | (48.04%) |
| Return on invested capital | 0.00% | 16.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack